ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO588

Urinary Treg and Th17 Cells Identify Active Renal Disease in Patients with ANCA-Associated Vasculitis

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation

Authors

  • Sonnemann, Janis, Charité - Universitätsmedizin Berlin, Berlin, Germany
  • Klocke, Jan, Charité - Universitätsmedizin Berlin, Berlin, Germany
  • Enghard, Philipp, Charité - Universitätsmedizin Berlin, Berlin, Germany
  • Eckardt, Kai-Uwe, Charité - Universitätsmedizin Berlin, Berlin, Germany
  • Schreiber, Adrian, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background

ANCA-associated vasculitides (AAV) cause necrotizing crescentic glomerulonephritis which is a major contributor to morbidity and mortality in AAV. As therapy relies on immunosuppressive agents with potential adverse effects, a reliable non-invasive biomarker of disease activity is needed to determine the right balance between over- and undertreatment. Since the pathogenic role of Tcells in AAV is emerging, we hypothesized that these subsets are increased in urine in active renal AAV and represent a reliable biomarker of disease activity.

Methods

Levels of Tcells and their subsets were measured in peripheral blood and urine samples from patients with active renal AAV (n=39), active non-renal AAV (n=9), AAV in remission (n=22), and healthy controls (n=9) using flow-cytometry. Urinary metabolites and cytokines (MCP-1, sCD163, sCD25, and C5a) were quantified by multiplex-analysis.

Results

Patients with active renal vasculitis show significantly higher urinary T cell counts than active non-renal, inactive, and healthy controls. In particular CD4+ T cells, T regulatory cells, and Th17 cells are significantly elevated compared to all controls. No significant difference could be shown for CD8+ T cells between active renal and remission. The only significant difference for Th1 cells was was found between active renal vasculitis and healthy controls.
sCD163, MCP-1, and C5a all show a significantly elevated concentration compared to patients in remission only sCD163 reaches significance for active renal vs. active non-renal. Analysis of receiver operator characteristics (ROC) reveals that urinary T cells identify active renal vasculitis with at least comparable diagnostic accuracy, CD3+, CD4+, CD8+ and Treg outperform soluble markers based on area under the curve (Treg AUC 0.93, sensitivity 79%, specificity 95%; CD3 Tcells AUC 0.95; sensitivity 92%, specificity 95%; MCP-1 AUC 0.9; sensitivity 60% specificity 100%, sCD163 AUC 0.92, sensitivity 96%, specificity 85%) .

Conclusion

Urinary Tcells are significantly elevated in active renal AAV and reliably determine renal disease activity. Biomarker performance for Tregs is comparable to published results of urinary MCP-1 and sCD163 and exceeds sCD25 and C5a while Th17 outperforms only sCD25 and C5a. Hence, urinary Tregs and Th17 are new potential biomarkers in AAV.